Wall Street brokerages expect that Voyager Therapeutics Inc (NASDAQ:VYGR) will announce sales of $5.25 million for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Voyager Therapeutics’ earnings. The lowest sales estimate is $2.00 million and the highest is $11.00 million. Voyager Therapeutics posted sales of $2.58 million during the same quarter last year, which suggests a positive year over year growth rate of 103.5%. The company is scheduled to announce its next quarterly earnings report on Tuesday, August 6th.
On average, analysts expect that Voyager Therapeutics will report full year sales of $29.94 million for the current financial year, with estimates ranging from $5.00 million to $81.57 million. For the next year, analysts forecast that the business will post sales of $52.20 million, with estimates ranging from $7.60 million to $95.57 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Voyager Therapeutics.
Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Tuesday, May 7th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of $0.65 by ($1.46). Voyager Therapeutics had a negative net margin of 804.55% and a negative return on equity of 129.67%. The company had revenue of $5.20 million during the quarter, compared to analyst estimates of $3.00 million.
A number of analysts have weighed in on the stock. Morgan Stanley upgraded shares of to an “overweight” rating and set a GBX 400 ($5.23) target price on the stock in a research report on Friday. HC Wainwright raised their target price on shares of Cytokinetics from $21.00 to $26.00 and gave the company a “buy” rating in a research report on Monday, May 6th. Nomura raised their target price on shares of Voyager Therapeutics from $26.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, June 20th. ValuEngine upgraded shares of Yelp from a “sell” rating to a “hold” rating in a research report on Wednesday, April 3rd. Finally, Wedbush restated an “outperform” rating and issued a $74.00 target price on shares of Tempur Sealy International in a research report on Tuesday, June 18th. Two research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Voyager Therapeutics has a consensus rating of “Buy” and an average price target of $27.44.
Voyager Therapeutics stock traded down $0.17 during mid-day trading on Friday, reaching $25.50. The company had a trading volume of 433,299 shares, compared to its average volume of 512,757. Voyager Therapeutics has a fifty-two week low of $7.76 and a fifty-two week high of $28.79. The firm has a market cap of $945.49 million, a P/E ratio of -9.27 and a beta of 2.57. The company has a fifty day moving average of $25.27.
Hedge funds have recently added to or reduced their stakes in the company. SG3 Management LLC bought a new position in shares of Voyager Therapeutics during the first quarter valued at $57,000. BNP Paribas Arbitrage SA raised its stake in shares of Voyager Therapeutics by 74,766.7% during the first quarter. BNP Paribas Arbitrage SA now owns 4,492 shares of the company’s stock valued at $86,000 after acquiring an additional 4,486 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its stake in shares of Voyager Therapeutics by 449.4% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock valued at $85,000 after acquiring an additional 7,401 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Voyager Therapeutics by 211.0% during the fourth quarter. Bank of America Corp DE now owns 10,637 shares of the company’s stock valued at $100,000 after acquiring an additional 7,217 shares during the last quarter. Finally, AlphaCrest Capital Management LLC bought a new position in shares of Voyager Therapeutics during the fourth quarter valued at $102,000. 73.78% of the stock is owned by hedge funds and other institutional investors.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.
Further Reading: What is an overbought condition?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.